NCT05377905View on ClinicalTrials.gov

Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 13, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

December 31, 2026

Conditions
Cutaneous Squamous Cell CarcinomaSkin Cancers - Squamous Cell Carcinoma
Interventions
DRUG

Microneedle Array Doxorubicin (MNA-D)

The Microneedle array patch is loaded/prepared with a total dose of 50 micrograms of Doxorubicin and is applied to a single selected cSCC remnant for a period of 20 minutes for a total of 4 weekly applications

Trial Locations (1)

15213

RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Falo, Louis, MD

OTHER